|
| |
Rib-XRib-X Pharmaceuticals, Inc. is a New Haven, CT-based small molecule drug discovery company focused on the structure-based design of classes of anti-infective agents. Our technology platform is based on the high resolution crystal structure of the 50S subunit of the ribosome obtained by Thomas Steitz, Peter Moore and their co-workers. Since the publication of their work (Science 289:905-929), their crystallography studies have advanced to include analysis of the structure of known antibiotics bound to the ribosome. The structural data from the antibiotic binding studies will be used at Rib-X to prime parallel lead optimization programs focused on evaluating new chemistry ideas about antibiotic interactions with the multiple binding domains or drug targets within the 50S subunit. Using proprietary computational chemistry tools provided by another scientific founder, Yale Professor William Jorgensen, coupled with chemical synthesis, biochemistry and crystallographic analysis, we aim to discover new compounds useful as anti-infective agents.
We believe Rib-X technology will offer a competitive advantage because many classical antibiotics work by inhibiting the function of the ribosome. Pfizer’s $1.4B a year block buster antibiotic, Zithromax, is a well-known example. Until the completion of the research endeavor of Steitz and Moore, the modes of action of these antibiotics have not been understood in chemical terms.
During the first two (2) years, the research goal will be to use the 50S subunit structural data to design a proprietary class of antibacterial agent that has broad-spectrum activity against antibiotic-resistant microorganisms. The medical need, the increase in antibiotic resistance and the difficulty in identifying new antibiotics is well documented in both the popular and scientific press. The current marketplace and low representation of new classes of antibiotics in clinical trials underscores the continuing value of identifying new agents.
| Contact Details: |
| 25 Science Park, Suite 561 |
| New Haven |
| CT |
| 06511 |
| United States of America |
| Tel: | (203) 624 5606 |
| Fax: | (203) 624 5627 |
| Email: | |
|
Loading...
|
Recent Publications by Rib-X: |  |
The use of ribosomal crystal structures in antibiotic drug design.
The ribosome is one of the richest validated targets for antibacterial... | 4th August, 2009
| Rib-X Pharmaceuticals Inc, Department of Structure-Based Drug Design, 300
| Curr Opin Investig Drugs. 2009 Aug;10(8):750-65.
|
Design at the atomic level: generation of novel hybrid biaryloxazolidinones as promising new antibiotics.
From the X-ray crystal structures of linezolid and the non-selective... | 10th January, 2009
| Department of Medicinal Chemistry, Rib-X Pharmaceuticals Inc., 300 George
| Bioorg Med Chem Lett. 2008 Dec 1;18(23):6179-83. Epub 2008 Oct 7.
DOI Direct Link |
Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics.
We have developed a first generation of hybrid sparsomycin-linezolid... | 10th January, 2009
| Department of Medicinal Chemistry, Rib-X Pharmaceuticals Inc., 300 George
| Bioorg Med Chem Lett. 2008 Dec 1;18(23):6175-8. Epub 2008 Oct 7.
DOI Direct Link |
R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.
New and improved antibiotics are urgently needed to combat the... | 10th January, 2009
| Rib-X Pharmaceuticals, Inc., 300 George Street, Suite 301, New Haven, CT
| Antimicrob Agents Chemother. 2008 Oct;52(10):3550-7. Epub 2008 Jul 28.
DOI Direct Link |
Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit.
The oxazolidinone antibacterials target the 50S subunit of prokaryotic... | 6th September, 2008
| Department of Structure-Based Drug Design, Rib-X Pharmaceuticals Inc, 300
| J Med Chem. 2008 Jun 26;51(12):3353-6.
DOI Direct Link |
→View more Rib-X research publications. |
Press Releases on Rib-X:
|
 |
| Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018 |
16th November, 2009 |
Decision Resources |
WALTHAM, Mass., Nov. 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, over the next decade,
|
| Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry |
7th October, 2009 |
Rib-X Pharmaceuticals, Inc. |
NEW HAVEN, Conn., Oct. 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic
|
| Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors |
30th June, 2009 |
Rib-X Pharmaceuticals, Inc. |
NEW HAVEN, Conn., June 30 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a development stage company focused on the discovery and development of novel antibiotics for the treatment of antibiotic
|
| Rib-X Pharmaceuticals Announces Presentations at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) |
7th May, 2009 |
Rib-X Pharmaceuticals, Inc. |
NEW HAVEN, Conn., May 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel
|
| Rib-X Granted Key Antibiotic Patent in China |
15th April, 2009 |
Rib-X Pharmaceuticals, Inc. |
NEW HAVEN, Conn., April 15 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery and development of novel
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 741 times since April 2007, the link to the organisation's website has been followed 0 times Search for more companies in New Haven Search for more companies in CT This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for Rib-X |
